Together with the trend of a poorer DFS and OS in Barx2-negative tumors than in Barx2-positive tumors, we conclude that the decreased Barx2 expression likely correlates with tumor invasion and metastasis and provides a novel biomarker for a highly malignant GC phenotype. This evidence concerns the gene BARX2 and neoplasm.